PreemptiveAI vs ArteraAI
A side-by-side comparison built from both listings. Blank cells mean the company has not given that detail; we never guess.
PreemptiveAI compared with ArteraAI
| Detail | 
PreemptiveAI | 
ArteraAI |
|---|
| What it does | Measure physiology in 30 seconds from any smartphone using optical blood-flow signals
| Personalized precision medicine powered by AI for cancer therapy
|
|---|
| Stage | Not given
| Not given
|
|---|
| Founded | Not given
| Not given
|
|---|
| Based in | US
| US
|
|---|
| Pricing model | Not given
| Contact for pricing
|
|---|
| Pricing | Not given
| Not given
|
|---|
| Key features | - 30-second fingertip scan via smartphone camera
- Foundation model trained on 12M+ waveforms
- Works across 200+ smartphone camera modules
- Personal baseline calculation (You vs. You)
- Camera-native mobile SDK for iOS and Android
- High-dimensional physiological embeddings via API
- Hemodynamics and arterial compliance analysis
- Longitudinal baseline divergence detection
- FDA-cleared core technology
- HIPAA compliant and 21 CFR Part 11 architecture
| - Analyzes digital pathology with no additional tissue staining required
- Rapid results within 1-2 days after specimen receipt
- Validated across diverse populations including African American and non-African American men
- FDA De Novo authorization for prostate cancer risk stratification
- Insurance coverage for Medicare and many commercial plans
- Provides 5 and 10-year distant metastasis risk for breast cancer
- Identifies breast cancer patients who benefit from chemotherapy
- Included in NCCN Clinical Practice Guidelines for Prostate Cancer
|
|---|
| What makes it different | - No dedicated wearable or hardware required—uses phones people already own
- Personalized 128-dimensional embeddings from first scan
- Active clinical validation through Medicare-funded deployment
- Compounding value from longitudinal data over time
- Deep learning from 12M+ paired clinical waveforms
| - No additional tissue preparation needed, uses existing H&E slides
- Validated across multiple large randomized phase III clinical trials
- FDA De Novo clearance as Software as a Medical Device
- Financial assistance program to make tests affordable regardless of income
|
|---|
| Community votes | 0 | 0 |
|---|
| DR (Domain Rating by Ahrefs) | 17 ▼ −1 (down) since last check | 57 ● no change since last check |
|---|
| Trust Flow (Majestic) | 6 | 15 |
|---|
| Citation Flow (Majestic) | 25 | 27 |
|---|
| Referring domains (Majestic) | 64 | 285 |
|---|
4 details filled in for both companies.
More alternatives to PreemptiveAI More alternatives to ArteraAI